ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Coronavirus-canSARVfinal_pdf_20200507.pdf (2.09 MB)

Coronavirus canSAR – a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community

preprint
submitted on 12.05.2020, 09:30 and posted on 07.08.2020, 21:00 by Costas Mitsopoulos, Albert A. Antolin, Eloy Villasclaras Fernandez, Patrizio Di Micco, Ioan L. Micca, Joseph E Tym, Ka Hing Che, James Campbell, Domenico Sanfelice, Ian Collins, Paul Workman, Bissan Al-Lazikani

We describe an AI-enabled, integrated Coronavirus drug discovery knowledgebase, free for the research community. Its goal is to make accessible up to date information relevant to drug discovery for SARS-CoV-2 and other coronaviruses. It builds on great knowledge from across therapeutic areas and provides unbiased, systematic, objective information to empower the international effort.

Funding

Cancer Research UK (C35696/A23187)

Wellcome Trust (WT212969/Z/18/Z)

Wellcome Trust (WT204735/Z/16/Z)

History

Email Address of Submitting Author

Bissan.Al-Lazikani@icr.ac.uk

Institution

THE INSTITUTE OF CANCER RESEARCH

Country

United Kingdom

ORCID For Submitting Author

0000-0003-3367-2519

Declaration of Conflict of Interest

CM, AAA, EVF, PdM, ILM, JET, KHC, JC, DS, IC, PW and BAL are employees of the Institute of Cancer Research (ICR) which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. PW is a former employee of AstraZeneca and received research funding from Vernalis, Astex, AstraZeneca, BACIT and Sixth Element Capital/CRT Pioneer Fund. PW is a consultant/scientific advisory board member for NextechInvest, Storm Therapeutics, Astex Pharmaceuticals and CV6, and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics. He is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Board Director of the nonprofit Chemical Probes Portal. BAL is currently or has been a consultant to Astex Pharmaceuticals, GSK, Astelas Pharma and Difiniens AG (member of Astra Zeneca group). BAL is a former employee of Inpharmatica Ltd. IC is currently or has been a consultant to Epidarex LLP, AdoRx Therapeutics and Enterprise Therapeutics, has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics and Sixth Element Capital/CRT Pioneer Fund, and holds stock in Monte Rosa Therapeutics AG. IC is a former employee of Merck Sharp & Dohme.

Exports